论文部分内容阅读
目的:观察FOLFOX 4与FLP化疗方案在晚期胃癌患者化疗中的疗效和毒副反应。方法:选取2011年1月—2012年9月我院的117例晚期胃癌住院患者,并均经病理确诊。FOLFOX 4方案:奥沙利铂(L-OHP)85mg/m2静滴,d1;氟尿嘧啶(5-FU)400mg/m2静推,600mg/m2持续静滴22h,d1～2;亚叶酸钙(LV)200mg/m2静滴2h,d1～2;3周为1个周期。FLP方案:顺铂(DDP)30mg/m2静滴,d1～3;5-FU 500mg/m2静滴4h,d1～5;LV200mg/m2静滴2h,d1～5;3周为1个周期。观察和比较FOLFOX 4与FLP两组的完全缓解情况和功能改善及毒副反应情况。结果:FOLFOX 4方案的总有效率为55.17%,FLP方案的总有效率为52.54%,两者无统计学差异(P>0.05)。两种化疗方案在改善患者的功能状态方面无差异(P>0.05)。FOLFOX 4方案组的神经毒性的发生率高于FLP组,而恶心呕吐的消化道反应的发生率明显低于FLP组(P<0.05)。结论:FOLFOX 4方案治疗晚期胃癌效果与FLP化疗方案相当,但是其毒副反应轻,患者生存质量改善更佳,可以作为胃癌晚期患者的化疗方案在临床上推广使用。
Objective: To observe the efficacy and side effects of FOLFOX 4 and FLP chemotherapy in chemotherapy of advanced gastric cancer patients. Methods: From January 2011 to September 2012, 117 cases of advanced gastric cancer hospitalized in our hospital were selected and confirmed by pathology. FOLFOX 4 regimen: intravenous infusion of 85 mg / m2 oxaliplatin (L-OHP), d1; 400 mg / m2 fluorouracil (5-FU) ) 200mg / m2 intravenous infusion 2h, d1 ~ 2; 3 weeks for a cycle. FLP program: cisplatin (DDP) 30mg / m2 intravenous infusion, d1 ~ 3; 5-FU 500mg / m2 intravenous infusion 4h, d1 ~ 5; LV200mg / m2 intravenous infusion 2h, d1 ~ 5; To observe and compare the two groups of FOLFOX 4 and FLP complete remission and improvement of function and toxic side effects. Results: The total effective rate of FOLFOX 4 regimen was 55.17%, and the total effective rate of FLP regimen was 52.54%. There was no significant difference between the two (P> 0.05). The two chemotherapy regimens in improving the functional status of patients no difference (P> 0.05). The incidence of neurotoxicity was higher in the FOLFOX 4 regimen than in the FLP group, whereas the incidence of nausea and vomiting was significantly lower in the gastrointestinal tract than in the FLP group (P <0.05). CONCLUSION: FOLFOX 4 regimen is equivalent to FLP chemotherapy in the treatment of advanced gastric cancer. However, its side effects are mild and its quality of life is better. It can be used clinically as a chemotherapy regimen for patients with advanced gastric cancer.